Dosing, administration, and safety of radium-223: How i do it

Tu D. Dan, Laura Doyle, Amar J. Raval, Andrew Pridjian, Leonard G. Gomella, Robert B. Den

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Radium-223 dichloride is a first-in-class bone-directed radiopharmaceutical that has been shown to prolong survival in men with metastatic castrate resistant prostate cancer (mCRPC). Unlike other radiopharmaceuticals, radium-223 uniquely uses alpha-emission to deliver high intensity, short range cytoxic treatments resulting in minimal myelosuppression. Following the results of the ALSYMPCA trial, radium-223 (Xofigo) was FDA approved in the United States in May 2013 and approved by Health Canada in December 2013 for the treatment of mCRPC with symptomatic bone metastases and no visceral disease. This "How I do it" article describes the background of radium 223 as well as the methods and techniques that our institution uses for safe and effective administration and notes the subtle differences when administering the drug in Canada.

Original languageEnglish (US)
Pages (from-to)8301-8305
Number of pages5
JournalCanadian Journal of Urology
Volume23
Issue number3
StatePublished - Jan 1 2016

Keywords

  • Alpharadin
  • Bone metastases
  • Metastatic prostate cancer
  • Radium-223

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Dosing, administration, and safety of radium-223: How i do it'. Together they form a unique fingerprint.

Cite this